Hot shot: the wider promise of weight-loss ja...

Is Binyamin Netanyahu’s time up as Israel’s prime minister? As a vote in parliament triggers the election campaign, our correspondent – and Netanyahu’s biographer – analyses what comes next. We join a US-backed counter-terrorism training exercise in Africa and question whether su ...  Show more

The latest Ebola emergency is different from previous ones: there is no vaccine, and the kind of community-level work that stops the spread has been thinned by aid cuts. Britain is likely to get a new prime minister soon; we profile Andy Burnham, the Labour party’s polling favour ...  Show more

Snack-food companies have long shown their adaptability to changing diets. How could the rise of appetite-suppressing drugs and fears about ultra-processed foods change the food we consume? How hearing aids and other lifestyle choices can reduce your risk of dementia (11:00). And ...  Show more

Falling fertility makes a global decline in population inevitable. That will change the shape and make up of societies. But it may not make us poorer. Are large language models really woke? And reading is on the wane – and why that matters. Listen to what matters most, from globa ...  Show more

America’s health secretary, RFK Jr, is known for his opposition to vaccines, particularly mRNA jabs, that have the potential to treat a large swathe of diseases. Slashing funding will have long term implications beyond America. Our correspondent visits Britain’s biggest and newes ...  Show more

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...